利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.04 秒)

    Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
    4.
    发明授权
    Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis 失效
    肿瘤标志物蛋白及其抗体用于癌症风险评估或诊断

    公开(公告)号：US5310653A

    公开(公告)日：1994-05-10

    申请号：US12972

    申请日：1993-02-02

    申请人： Margaret Hanausek-Walaszek ,  Thomas J. Slaga ,  Zbigniew Walaszek

    发明人： Margaret Hanausek-Walaszek ,  Thomas J. Slaga ,  Zbigniew Walaszek

    IPC分类号： C07K14/47 ,  C07K16/18 ,  G01N33/574 ,  A61K37/08 ,  A61K39/00 ,  C07K15/18

    CPC分类号： G01N33/57476 ,  C07K14/47 ,  C07K16/18 ,  G01N33/5743 ,  G01N33/57438 ,  G01N33/57496

    摘要： A tumor-associated marker protein was purified and antibodies thereto developed for cancer diagnosis and assessment of cancer risk associated with the long-term use of synthetic steroid hormones, both contraceptive and non-contraceptive, and other drugs that exhibit tumor promotional properties. The marker protein and antibodies thereto provided are interspecies immunologically cross-reactive.In summary, the marker p65 tumor-associated factor of the present invention has the following characteristics:(a) binds substantially completely to a phenyl hydrophobic interaction column in a buffer containing 20% ammonium sulfate and eluted at ca. 16% ammonium sulfate;(b) localized primarily in the nuclear envelopes with only small amounts present in the cytoplasm from where is released to the blood circulation in vivo or cell culture medium in vitro;(c) induced in normal, adult tissues by chemical carcinogens (initiators) but not by tumor promoters, the carcinogen-induced production being enhanced by the latter.Also disclosed herein are processes for purifying the 65 kDa tumor marker from plasma, tumor cytosol or ascitic fluid of carcinoma bearing animals; processes for producing antisera and purified antibody preparations to the 65 kDa tumor marker; and methods using antibody to the 65 kDa to diagnose or assess the likelihood of cancer.

    摘要翻译： 纯化了与肿瘤相关的标记蛋白，并且其抗体开发用于癌症诊断和评估与长期使用合成类固醇激素（避孕和非避孕药）以及其它展现肿瘤促进性质的药物相关的癌症风险。 标记蛋白及其提供的抗体是免疫交叉反应性的种间。 总之，本发明的标记p65肿瘤相关因子具有以下特征：（a）基本上完全与含有20％硫酸铵的缓冲液中的苯基疏水相互作用柱结合并在约5℃下洗脱。 16％硫酸铵; （b）主要在核包膜中定位，其中只有少量存在于细胞质中，其体内释放到体内血液循环或体外细胞培养基; （c）通过化学致癌物（引发剂）而不是由肿瘤启动子在正常的成年组织中诱导，致癌物诱导的生产由后者增强。 本文还公开了从承载动物的血浆，肿瘤细胞质或腹水中纯化65kDa肿瘤标志物的方法; 制备抗血清和纯化抗体制剂至65kDa肿瘤标志物的方法; 以及使用65kDa抗体诊断或评估癌症可能性的方法。

    Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of .beta.- g
    9.
    发明授权
    Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of .beta.- g 失效
    通过β-葡萄糖醛酸酶的缓释抑制剂减少内源和环境衍生化合物的不适当水平的体内

    公开(公告)号：US4845123A

    公开(公告)日：1989-07-04

    申请号：US762339

    申请日：1985-08-05

    申请人： Zbigniew Walaszek ,  Malgorzata Hanausek-Walaszek ,  Thomas E. Webb ,  John P. Minton

    发明人： Zbigniew Walaszek ,  Malgorzata Hanausek-Walaszek ,  Thomas E. Webb ,  John P. Minton

    IPC分类号： A61K31/19 ,  A61K31/365

    CPC分类号： A61K31/19 ,  A61K31/365

    摘要： A method for the reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by inhibiting the activity of .beta.-glucuronidase in a mammal which comprises the administration to the mammal of an effective amount of a water insoluble, or sparingly soluble, sustained release precursor of glucarolactone or its analog is disclosed. The sustained release precursor of glucarolactone compound is selected from the group consisting of D-glucaric acid, D-galactaric acid, and L-idaric acid or derivatives or analogs. An orally administrable preparation of the sustained release precursor of glucarolactone compound is provided in the form of a capsule tablet, such that the glucarolactone or its analog is slowly released in the stomach of the treated animal or human.

    摘要翻译： 一种通过抑制哺乳动物中β-葡糖醛酸糖苷酶的活性来减少内源和环境衍生化合物的不适当水平的方法，其包括向哺乳动物施用有效量的不溶于水的或微溶的持续的 公开了葡萄糖内酯或其类似物的释放前体。 葡萄糖内酯化合物的持续释放前体选自D-葡糖二酸，D-半乳糖酸，L-赖氨酸或其衍生物或类似物。 提供了可口服给药的葡萄糖内酯化合物的缓释前体，其形式为胶囊片剂，使得葡萄内酯酮或其类似物在经处理的动物或人的胃中缓慢释放。